Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 594,697
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $56,737,885
Total People Sold 5 5 6 7
Total Sell Transactions 11 15 24 53
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 2549
  Page 10 of 102  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Fuchs Henry J President, Worldwide R&D   •       –      –    2022-03-08 4 A $0.00 $0 D/D 12,840 119,323     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-03-08 4 A $0.00 $0 D/D 34,780 338,569     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2022-03-08 4 A $0.00 $0 D/D 9,370 65,223     -
   Slamon Dennis Director   –       •      –    2022-02-28 4 S $78.33 $501,013 D/D (6,396) 21,639     -
   Heron Elaine J Director   –       •      –    2022-02-25 4 OE $37.46 $318,410 D/D 8,500 80,588     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2022-02-03 4 D $87.77 $94,089 D/D (1,072) 29,709     -
   Lawlis V Bryan Director   –       •      –    2022-01-14 4 AS $87.61 $372,343 D/D (4,250) 23,970     -
   Lawlis V Bryan Director   –       •      –    2022-01-14 4 OE $37.46 $159,205 D/D 4,250 28,220     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-01-13 4 AS $87.86 $439,300 D/D (5,000) 303,789     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-01-13 4 OE $37.46 $187,300 D/D 5,000 308,789     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-01-12 4 AS $89.00 $445,000 D/D (5,000) 303,789     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-01-12 4 OE $37.46 $187,300 D/D 5,000 308,789     -
   Alles Mark J Director   –       •      –    2022-01-03 4 A $0.00 $0 D/D 2,300 2,300     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-12-21 4 A $89.22 $8,922 D/D 100 303,789     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-12-16 4 AS $84.68 $508,080 D/D (6,000) 303,689     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-12-16 4 OE $37.46 $224,760 D/D 6,000 309,689     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-12-15 4 AS $82.71 $496,260 D/D (6,000) 303,689     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-12-15 4 OE $37.46 $224,760 D/D 6,000 309,689     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-12-10 4 GD $0.00 $0 D/D 700 303,689     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2021-10-26 4 AS $73.60 $201,590 D/D (2,739) 55,853     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-10-20 4 OE $37.46 $37,460 D/D 1,000 305,839     -
   Davis George Eric EVP, General Counsel   •       –      –    2021-08-02 4 AS $76.69 $423,175 D/D (5,518) 58,590     -
   Acosta Andrea GVP, Chief Accounting Officer   •       –      –    2021-07-16 4 D $78.84 $22,469 D/D (285) 18,122     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2021-06-29 4 D $83.46 $48,073 D/D (576) 30,781     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2021-06-21 4 OE $37.46 $37,460 D/D 1,000 304,839     -
  2549 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 10 of 102
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us